Monday, October 3, 2022


Biotechnology News Magazine

Allied BioScience Continues Focus on Saving Lives – Expands Globally

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

March 30, 2021

Allied BioScience is growing significantly as the innovative biotech firm commits to expanding regulatory approvals for the use of SurfaceWise2™ nationally and abroad to meet demand while diversifying the lineup of products beyond antimicrobial surface coatings.

As global demand for SurfaceWise2 continues to expand, the company has strategic partnerships in Canada, Germany, Australia, India and the United Arab Emirates, with more in the pipeline. Spanning industries including transportation, healthcare, fitness and retail, leading partners in these countries plan to distribute and apply the surface coating.

“Allied BioScience has been committed to reducing the global burden of infectious disease for over a decade, but we’re especially proud of the innovation over the past year,” said Michael Ruley, CEO of Allied BioScience. “We remain focused on our mission as we expand globally, providing SurfaceWise2 to nations as part of the fight against COVID-19 and other viruses, and continue to diversify our products to keep our friends and families safer in new ways.”

Following initial emergency use authorization for SurfaceWise2 in the State of Texas by the Environmental Protection Agency, the company continues to work closely with the agency to increase access to the revolutionary residual COVID-19-fighting solution. The EPA recently announced the expansion of this authorization for the states of Oklahoma and Arkansas, as well as an approved extended residual efficacy of 30 days. Broad, national approval is expected in the coming months.

The company recently relocated its Plano headquarters to a new office space with nearly double its previous square footage to account for anticipated team expansion and plans to expand offerings outside of its flagship surface coatings in 2021.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine